Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection (Q45707657)

15 December 2017

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection (English)

1 reference

15 December 2017

0 references

1 reference

1 reference

7

Jürgen K Rockstroh

1 reference

15 December 2017

Nazifa Qurishi

1

1 reference

15 December 2017

Christina Kreuzberg

2

1 reference

15 December 2017

Guido Lüchters

3

1 reference

15 December 2017

Wolfgang Effenberger

4

1 reference

15 December 2017

Bernd Kupfer

5

1 reference

15 December 2017

Tilman Sauerbruch

6

1 reference

15 December 2017

Ulrich Spengler

8

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

15 December 2017

1 reference

15 December 2017

362

1 reference

15 December 2017

1708-1713

1 reference

15 December 2017

9397

1 reference

Prevalence of Antibody to Hepatitis C Virus in Patients Infected with the Human Immunodeficiency Virus

15 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Clearance of hepatitis G viremia in a human immunodeficiency virus-positive patient by high-activity antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Effects of HAART on hepatitis C, hepatitis G, and TT virus in multiply coinfected HIV-positive patients with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Lactic acidosis associated with stavudine administration: a report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

The clinical spectrum of hepatitis C virus in HIV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

An immunoassay for specific amplified HCV sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914844-1

7 January 2021

10.1016/S0140-6736(03)14844-1

Identifiers

DOI

1 reference

15 December 2017

1 reference